NewsRoom Articles - Page 57 of 154 - PsychedelicNewsWire (PNW)

ThursdayJun 09, 2022 3:35 pm

New Study Suggests That MDMA May Decrease Fear, Boost PTSD Treatment

A new study that looked into the relationship between an individual’s response to fear and the use of MDMA has found that combining this drug with recall therapy and fear extinction learning substantially decreased the fear felt by individuals involved in the study. This comes after MAPS recently released promising results from its phase III clinical trial, which found that MDMA-assisted therapy could be beneficial to patients with PTSD. The MindMed-linked research was carried out by scientists based at the University Hospital of Basel, which is located in Switzerland. Their objective was to test whether the use of MDMA could…

WednesdayJun 08, 2022 1:36 pm

Study Offers New Insights into Psilocybin’s Mechanism for Treating Depression

About 30% of individuals suffering from depression usually don’t benefit from treatment using antidepressants. This highlights the need to expand the collection of drugs available to individuals with depression. In the last few years, increasing evidence has found that psychedelic compounds such as psilocybin may be useful in the treatment of depression. Psilocybin is the active compound found in magic mushrooms that causes hallucinations when administered in large doses. However, while researchers know the drug can relieve depression by changing the response of an individual’s brain to serotonin, they don’t know much about the process of how the drug works…

TuesdayJun 07, 2022 12:14 pm

New Research Finds That Individuals Prefer Guide with Personal Psilocybin Experience

New research has found that individuals with symptoms of depression believe that it is crucial that guides who aid in psilocybin-assisted therapy have used the substance themselves. Guides are trained professionals who facilitate the psychedelic experience. Psilocybin is the active compound found in hallucinogenic mushrooms. It causes hallucinations when ingested in high doses. Various studies have found that the compound may be useful during the treatment for a range of mental health conditions, including depression. While it is possible for clients to have and value a guide that has used psilocybin previously, it may raise concerns or doubts among other…

MondayJun 06, 2022 2:48 pm

Researchers Look into Use of Psychedelics in Treating Autism

Various studies have found that psychedelics may provide the potential to treat a range of mental health conditions. Anecdotal evidence from individuals such as Aaron Orsini has also shown that drugs such as MDMA, psilocybin and LSD may be useful in managing autism. Orsini, who has in the last eight years or so consumed the aforementioned substances to help manage his autism symptoms, recently wrote a book detailing his experiences with psychedelics. Despite this, researchers are hesitant about the use of psychedelics by individuals with autism. Scientists know that psychedelic drugs primarily act on the serotonin system, which is already…

FridayJun 03, 2022 11:53 am

UK Firm Develops Inhaler to Facilitate Psychedelic Microdosing

Recently, NewTerritory announced that it had developed a wellness product that could be used to inhale psychedelic substances in microdoses. The design studio, which is based in the United Kingdom, anticipates that the drugs could soon be legalized for use in treating various mental health conditions. The proposal, which the company named Human Nature, imagines how LSD and psilocybin could be administered in small doses to improve an individual’s well-being. Psilocybin is the active compound found in magic mushrooms that causes hallucinations when consumed in large quantities. In theory, the drugs will be held in biodegradable capsules to be dispensed…

ThursdayJun 02, 2022 3:09 pm

Five Next-Gen Psychedelics Clinical Trials Taking Place in 2022

Numerous studies have shown that psychedelics may be useful in the treatment of mental health conditions, including depression and post-traumatic stress disorder. Companies such as MindMed, Cybin Inc. and Field Trip Health have been conducting clinical trials to test the safety and effectiveness of these medicines in comparison to currently used drugs. Below are some of the next-generation psychedelics that will be in trials this year. Cybin’s CYB003 candidate Cybin’s next-generation psilocybin candidate will enter a phase 1/2a trial this year, after the company receives regulatory approval. The focus of the trial will be the candidate’s effectiveness in treating major…

WednesdayJun 01, 2022 3:16 pm

Oregon Adopts First Installment of Psilocybin Rules

Last week, the Oregon Health Authority adopted new administrative rules to govern testing and training programs for psilocybin as well as psilocybin products. These rules, as well as others that have not yet been finalized, will go into effect in January 2023, when Oregon’s therapeutic psilocybin program begins. Earlier this year, the state published a draft of its proposed directives on psilocybin before it obtained feedback from its residents in April. According to Oregon Psilocybin Services (OPS), since then more than 200 verbal and written comments have been submitted. Consequently, last week OPS released a list of finalized rules, noting…

TuesdayMay 31, 2022 3:30 pm

UC Davis Awarded Grant to Find New Non-hallucinogenic Psychedelic Treatments for Addiction

Scientists at the University of Colorado Anschutz Medical Campus and the University of California Davis are planning to screen compounds in an effort to find new non-hallucinogenic treatments for substance-use disorders. This research will be funded by a $2.7 million grant that was awarded to the institutions by the National Institute on Drug Abuse. The studies are based on evidence from animal and human tests which suggest that psychedelics possess brain-altering effects that could be beneficial in the treatment of addiction. Prior research has also found that psychedelics rewire some regions in the brain that are involved in post-traumatic stress…

TuesdayMay 31, 2022 11:15 am

Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties

On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma focuses on palliative uses of psychedelics for “PTSD, Parkinson’s, and other rare neurological disorders.” In teaming up with TrPR. Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s Disease. Psilocybin’s journey from magic mushrooms to potential life savers has been a long,…

TuesdayMay 31, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000